Pharma Legal, Enforcement & Alert Intelligence
Source-linked judgments, compliance and enforcement developments, and regulatory alerts.
Court Judgments & Legal Opinions
Pharma-related cases, judgments, legal opinions and precedents.
148 recordsOpen Section →02
Compliance & Enforcement
Compliance requirements, inspections, violations, enforcement actions and recalls.
27 recordsOpen Section →03
Legal / Regulatory Alerts
Important legal and regulatory developments requiring attention.
503 recordsOpen Section →
Court Judgments & Legal Opinions · 148 visible records
High Courts of India
M/s Aventis Pharma Limited v. State of Jharkhand
Summary: The Jharkhand High Court considered compliance with sample-division requirements and the manufacturer’s opportunity to challenge the analyst result.
Outcome / action: The petition challenging continuation of the prosecution was dismissed after the Court found that the sampling procedure and preservation of portions presented matters to be assessed in the criminal case.
Practical impact: Keep complete Form 17/18, sample-chain, delivery and analyst-report records because procedural disputes may be left for trial.
Open source record →Narotam Chand v. State of Himachal Pradesh
Summary: The Himachal Pradesh High Court considered source disclosure, unlicensed stocking and which criminal court is competent to try Chapter IV offences.
Outcome / action: The petition was partly allowed: the Section 18A/28 charge was set aside because purchase invoices disclosed the source, while trial for unlicensed stocking or sale under Sections 18(c) and 27(b)(ii) was permitted to continue.
Practical impact: Purchase invoices may satisfy source-disclosure duties, but they do not replace the licence required for stocking or sale; charging orders should separate the two issues.
Open source record →Yashpaul Chail & Others v. State of Uttar Pradesh through Inspector of Drugs
Summary: The Allahabad High Court examined sampling compliance, analyst-report safeguards and responsibility of company officers in an NSQ-drug complaint.
Outcome / action: The Court granted relief in the challenge to prosecution, considering the absence of relevant director responsibility and the statutory requirements governing sampling and the opportunity to controvert the analyst report.
Practical impact: Create the required sample portions, preserve the Section 25 remedy and establish an officer’s role at the relevant manufacturing or supply date.
Open source record →AstraZeneca AB & Another v. Azista Industries Pvt. Ltd. & Others
Summary: The Delhi High Court considered allegations involving import, online listing and sale of Osimertinib products and the role of CDSCO permission under Rule 36 for import for personal use.
Outcome / action: The Court recorded undertakings concerning import under Rule 36, directed removal of identified online listings, and granted interim restraint against dealing in the allegedly infringing Osimertinib product.
Practical impact: Online marketplaces and suppliers should ensure that prescription-drug listings, imports and sales comply with applicable patent rights and CDSCO permissions. The order is interim and should not be described as a final determination of the suit.
Open official source →M/s Hetero Labs Limited & Others v. Union of India through Drug Inspector
Summary: The Himachal Pradesh High Court considered the conclusive statutory effect of a Central Drugs Laboratory report favourable to the manufacturer.
Outcome / action: The proceedings were treated as unsustainable because the Central Drugs Laboratory report found the sample conforming to specifications and conclusively superseded the contrary Government Analyst report.
Practical impact: Once a valid CDL report is produced, its Section 25(4) conclusion governs the tested facts and should control further prosecution decisions.
Open source record →Sudeep Kumar Garnaik & Another v. State of Odisha
Summary: The Orissa High Court considered pre-arrest bail for retail and supply-chain participants in a case involving allegedly spurious capsules with nil active ingredients.
Outcome / action: Anticipatory bail was rejected because the alleged capsules contained none of the declared active ingredients, creating a serious prima facie spurious-drug and public-health case requiring custodial investigation.
Practical impact: Retailers and wholesalers should verify licensed sources and preserve purchase records; courts may treat alleged spurious medicines as grave public-health offences at the bail stage.
Open source record →Sanjeev Wasan v. Union of India
Summary: The Madras High Court reviewed individual director liability in a prosecution concerning an allegedly spurious drug.
Outcome / action: The petition was allowed and proceedings were quashed against the petitioner-director alone because the complaint and supporting material did not show that he controlled the company’s day-to-day manufacturing business.
Practical impact: A director’s title alone is insufficient; complaints should connect the person with relevant business or manufacturing responsibility.
Open source record →B. Sanjay Kumar v. State of Tamil Nadu
Summary: The Madras High Court reviewed prosecution involving Action 500 Extra and storage in a part of the premises not covered by the licence.
Outcome / action: The petition was allowed and proceedings were quashed; stocking at the ground floor instead of the licensed first floor was treated, on the case facts, as causing only slight harm.
Practical impact: Every storage floor should be covered by the licence, although highly fact-specific triviality principles may affect criminal proceedings.
Open source record →Dr. D. Bhaskara Rao v. State of Telangana
Summary: The Telangana High Court examined medicines held in different licensed hospital wings and nursing stations for inpatient treatment.
Outcome / action: The petition was allowed and proceedings against the hospital managing director were quashed because the medicines were stored at nursing stations for administration to identified inpatients rather than for an unlicensed sale.
Practical impact: Hospitals should maintain pharmacy requisitions, patient-linked issue records and site-specific licences to show the purpose and chain of internal medicine movement.
Open source record →Shailyamanyu Singh v. State of Maharashtra
Summary: The Bombay High Court distinguished mere designation from specific allegations of consent, connivance or neglect in unlicensed drug distribution.
Outcome / action: The applications were dismissed because the complaint contained sufficient specific allegations of distribution to an unlicensed person to support a prima facie inference under Section 34(2).
Practical impact: Section 34 pleadings should state the officer’s specific conduct; detailed distribution allegations may justify continuation of prosecution.
Open source record →Anav Jain v. State of Haryana
Summary: The Punjab and Haryana High Court considered Bhang extract used for Ayurvedic medicines, manufacturing licences and the boundary between drug regulation and NDPS prosecution.
Outcome / action: The petition was allowed and the NDPS FIR and consequential proceedings were quashed because the recovered Bhang extract was linked to licensed Ayurvedic manufacture and the statutory NDPS basis was not established.
Practical impact: Ayurvedic manufacturers should maintain current product, manufacturing and possession licences; enforcement must identify the correct controlled substance and statutory authority.
Open source record →Supreme Court of India
Lalankumar Singh & Others v. State of Maharashtra
Summary: The Supreme Court examined prosecution of directors concerning Hemfer syrup reported not of standard quality and the requirements for vicarious liability and issuance of process.
Outcome / action: The appeal was allowed and the process and proceedings were quashed because the complaint lacked specific allegations of director responsibility and the Magistrate had not issued a reasoned process order.
Practical impact: Identify the approved manufacturing and testing personnel, plead each director’s actual role and ensure the Magistrate records sufficient grounds when issuing process.
Open source record →High Courts of India
Nirma Limited through Ajay Bhushanlal Nanavati v. State of Gujarat
Summary: The Gujarat High Court reviewed prosecution concerning Gentamicin injection and the distinction between minor NSQ defects and cases warranting criminal action.
Outcome / action: The petition was allowed and the complaint and summons were quashed; the Court considered the alleged particulate-matter issue, product withdrawal and guidelines favouring administrative measures for minor defects.
Practical impact: NSQ enforcement should document defect severity, public-health risk and why administrative measures would be inadequate.
Open source record →M/s Celebrity Biopharma Limited & Others v. Union of India
Summary: The Calcutta High Court considered an NSQ and alleged misbranding prosecution involving pH specifications, sample procedure and process against company officers located outside Kolkata.
Outcome / action: The revisional application was allowed and the complaint was quashed, including because the mandatory Section 202 CrPC inquiry was not conducted before process issued against accused outside the Magistrate’s jurisdiction.
Practical impact: Follow statutory sample-disposal safeguards, plead each officer’s actual role and complete the mandatory territorial inquiry before issuing criminal process.
Open source record →M/s Carenow Medical Pvt. Ltd. v. Drugs Inspector
Summary: The Madras High Court considered hand-rub labelling, misbranding and the regulatory guidelines distinguishing minor defects from violations warranting criminal prosecution.
Outcome / action: Both petitions were allowed and the prosecutions were quashed; the small label variation was treated as a minor defect rather than a false or misleading statement amounting to misbranding.
Practical impact: Regulators should distinguish minor label variations suitable for administrative measures from intentional or materially misleading claims.
Open source record →M/s Zest Pharma & Others v. State represented by the Drugs Inspector
Summary: The Madras High Court considered a challenge to prosecution based on an asserted request to controvert the Government Analyst report and obtain reanalysis.
Outcome / action: The quashing petition was dismissed; the disputed question whether a timely request for reanalysis had been sent was left for determination at trial.
Practical impact: Retesting requests and proof of delivery should be documented clearly because disputed communication may require evidence at trial.
Open source record →Supreme Court of India
Union of India v. Ashok Kumar Sharma & Others
Summary: The Supreme Court considered the respective powers of Drug Inspectors and police when offences under Chapter IV of the Drugs and Cosmetics Act are alleged.
Outcome / action: The Court held that police cannot investigate and prosecute Chapter IV Drugs and Cosmetics Act offences through the ordinary police-report route where Section 32 governs institution of prosecution, while preserving action for distinct offences under other laws.
Practical impact: Before initiating or assessing a prosecution, verify whether the complaint and investigation were undertaken by an authority permitted under Section 32 and distinguish any separate penal-code offence.
Open official source →High Courts of India
Applicant v. State of Uttarakhand
Summary: The Uttarakhand High Court examined trial-court competence after the State designated a Sessions Court as Special Court for specified drug offences.
Outcome / action: The application was allowed and the summoning order and proceedings were quashed because the complaint had been filed before a Chief Judicial Magistrate rather than the notified Special Court; fresh filing before the competent court remained open.
Practical impact: Before filing, verify whether the alleged offence belongs before a Magistrate, Sessions Court or notified Special Court under the applicable statutory and notification framework.
Open source record →M/s Laborate Pharmaceuticals India Ltd. v. State of Jammu & Kashmir & Others
Summary: The High Court considered whether prosecution could continue after the sampled drug expired and the manufacturer could no longer obtain Central Drugs Laboratory reanalysis.
Outcome / action: The petition was allowed and the complaint and consequential orders were quashed because prosecution delay and shelf-life expiry deprived the manufacturer of the Sections 25(3) and 25(4) reanalysis right.
Practical impact: Sampling portions, analyst reports, prosecution filing and cognizance should be completed in time to preserve the accused’s statutory reanalysis remedy.
Open source record →Supreme Court of India
Union of India & Another v. Pfizer Limited & Others
Summary: The Supreme Court examined challenges relating to Central Government notifications issued under Section 26A concerning prohibition of specified drugs and fixed-dose combinations.
Outcome / action: The appeals concerning Section 26A prohibition notifications were decided with directions addressing the challenged regulatory decision-making process and expert examination.
Practical impact: Section 26A prohibition decisions and related challenges must be assessed against the statutory process, the supporting expert material and the precise notification applicable to the product.
Open official source →